Abstract

Recent clinical trials have shown that the circulating Endothelial Progenitor Cells (EPCs) may act as a powerful endogenous reparative system in several cardiovascular diseases including Heart Failure (HF). Indeed, endothelial repair and restoring endothelial function is considered a target for several treatment approaches, which are widely used in HF care. It is known that a number of circulating EPCs decreased sufficiently depending on severity of cardiac dysfunction. Moreover, lowered count of EPCs was found promising biomarker of HF-related outcomes. Nowadays there is a large body of evidence regarding considerable discriminant of lowered EPCs with different immune phenotypes in HF with different etiologies. The short commentary is depicted the role of measurement of EPC count in HF individuals aimed to improve the predictive value of contemporary used biomarker-based scales.